Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step

Table 4

Univariate and multivariate cox regression analysis of clinical, immunological, and therapeutic covariates to predict allograft loss following ABMR treatment. Covariates were only considered for the multivariate cox regression model if statistically significant in the univariate analysis.

	HR	95% CI
Univariate
Retransplantation	1.70	0.66–4.37	0.27
Induction therapy by IL-2R antibody	0.82	0.31–2.13	0.68
Early ABMR	0.97	0.38–2.47	0.95
eGFR < 30 mL/min/1.73 m^2 at ABMR diagnosis	2.67	1.07–6.63	0.03
Chronic glomerulopathy (cg) score ≥ 1 at ABMR diagnosis	1.69	0.71–4.01	0.23
DSA class I	0.65	0.28–1.50	0.31
DSA class II	0.82	0.30–2.24	0.70
DSA class I + II	0.77	0.32–1.88	0.57
DSAmax > 10,000 MFI	1.57	0.69–3.57	0.28
Everolimus-based maintenance immunosuppression	0.52	0.07–3.94	0.52
ABMR treatment by rituximab	2.74	1.16–6.47	0.02
ABMR treatment by bortezomib	0.37	0.15–0.86	0.02
ABMR treatment by high-dose IVIG	0.34	0.13–0.93	0.04
Multivariate
ABMR treatment by rituximab + low-dose IVIG (RLP)	1.00	n.a.	n.a
ABMR treatment by bortezomib + low-dose IVIG (BLP)	0.58	0.22–1.52	0.27
ABMR treatment by bortezomib + high-dose IVIG (BHP)	0.21	0.07–0.62	0.005
eGFR < 30 mL/min/1.73 m^2 at ABMR diagnosis	3.26	1.29–8.24	0.01

DSA, donor-specific HLA antibody(ies), HR, hazard ratio, MFI, mean fluorescence intensity, n.a., not applicable, 95%CI, confidence interval 95%.